RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

被引：23

作者：

Pan, Xiaoyan ^{[1
,2
,3
]}

Shi, Jian ^{[4
]}

Hu, Xue ^{[1
,3
]}

Wu, Yan ^{[1
]}

Zeng, Liang ^{[4
]}

Yao, Yanfeng ^{[3
]}

Shang, Weijuan ^{[1
]}

Liu, Kunpeng ^{[1
,2
]}

Gao, Ge ^{[3
]}

Guo, Weiwei ^{[1
,2
]}

Peng, Yun ^{[3
]}

Chen, Shaohong ^{[1
]}

Gao, Xiaoxiao ^{[3
]}

Peng, Cheng ^{[3
]}

Rao, Juhong ^{[1
,2
]}

Zhao, Jiaxuan ^{[1
,2
]}

Gong, Cheng ^{[4
]}

Zhou, Hui ^{[4
]}

Lu, Yudong ^{[4
]}

Wang, Zili ^{[4
]}

Hu, Xiliang ^{[4
]}

Cong, WenJuan ^{[4
]}

Fang, Lijuan ^{[4
]}

Yan, Yongxiang ^{[4
]}

Zhang, Jing ^{[4
]}

Xiong, Hui ^{[4
]}

Yi, Jizu ^{[4
]}

Yuan, Zhiming ^{[1
,2
,3
]}

Zhou, Pengfei ^{[4
]}

Shan, Chao ^{[1
,2
,3
]}

Xiao, Gengfu ^{[1
,2
,3
]}

机构：

[1] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan, Hubei, Peoples R China

[2] Univ Chinese Acad Sci, Beijing, Peoples R China

[3] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, Wuhan, Hubei, Peoples R China

[4] Wuhan YZY Biopharma Co Ltd, Wuhan, Hubei, Peoples R China

来源：

CELL DISCOVERY | 2021年 / 7卷 / 01期

基金：

国家重点研发计划;

关键词：

SARS-COV-2;

D O I：

10.1038/s41421-021-00320-y

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.

引用

页数：15

共 49 条

[31] Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes [J].

Saad-Roy, Chadi M. ;

Morris, Sinead E. ;

Metcalf, C. Jessica E. ;

Mina, Michael J. ;

Baker, Rachel E. ;

Farrar, Jeremy ;

Holmes, Edward C. ;

Pybus, Oliver G. ;

Graham, Andrea L. ;

Levin, Simon A. ;

Grenfell, Bryan T. ;

Wagner, Caroline E. .

SCIENCE, 2021, 372 (6540) :363-370

[32] Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques [J].

Shan, Chao ;

Yao, Yan-Feng ;

Yang, Xing-Lou ;

Zhou, Yi-Wu ;

Gao, Ge ;

Peng, Yun ;

Yang, Lian ;

Hu, Xue ;

Xiong, Jin ;

Jiang, Ren-Di ;

Zhang, Hua-Jun ;

Gao, Xiao-Xiao ;

Peng, Cheng ;

Min, Juan ;

Chen, Ying ;

Si, Hao-Rui ;

Wu, Jia ;

Zhou, Peng ;

Wang, Yan-Yi ;

Wei, Hong-Ping ;

Pang, Wei ;

Hu, Zheng-Fei ;

Lv, Long-Bao ;

Zheng, Yong-Tang ;

Shi, Zheng-Li ;

Yuan, Zhi-Ming .

CELL RESEARCH, 2020, 30 (08) :670-677

[33] Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment [J].

Sun, Jing ;

Zhuang, Zhen ;

Zheng, Jian ;

Li, Kun ;

Wong, Roy Lok-Yin ;

Liu, Donglan ;

Huang, Jicheng ;

He, Jiangping ;

Zhu, Airu ;

Zhao, Jingxian ;

Li, Xiaobo ;

Xi, Yin ;

Chen, Rongchang ;

Alshukairi, Abeer N. ;

Chen, Zhao ;

Zhang, Zhaoyong ;

Chen, Chunke ;

Huang, Xiaofang ;

Li, Fang ;

Lai, Xiaomin ;

Chen, Dingbin ;

Wen, Liyan ;

Zhuo, Jianfen ;

Zhang, Yanjun ;

Wang, Yanqun ;

Huang, Shuxiang ;

Dai, Jun ;

Shi, Yongxia ;

Zheng, Kui ;

Leidinger, Mariah R. ;

Chen, Jiekai ;

Li, Yimin ;

Zhong, Nanshan ;

Meyerholz, David K. ;

McCray, Paul B., Jr. ;

Perlman, Stanley ;

Zhao, Jincun .

CELL, 2020, 182 (03) :734-+

[34] Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine [J].

Tai, Wanbo ;

He, Lei ;

Zhang, Xiujuan ;

Pu, Jing ;

Voronin, Denis ;

Jiang, Shibo ;

Zhou, Yusen ;

Du, Lanying .

CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (06) :613-620

[35] A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses [J].

Tauzin, Alexandra ;

Nayrac, Manon ;

Benlarbi, Mehdi ;

Gong, Shang Yu ;

Gasser, Romain ;

Beaudoin-Bussieres, Guillaume ;

Brassard, Nathalie ;

Laumaea, Annemarie ;

Vezina, Dani ;

Prevost, Jeremie ;

Anand, Sai Priya ;

Bourassa, Catherine ;

Gendron-Lepage, Gabrielle ;

Medjahed, Halima ;

Goyette, Guillaume ;

Niessl, Julia ;

Tastet, Olivier ;

Gokool, Laurie ;

Morrisseau, Chantal ;

Arlotto, Pascale ;

Stamatatos, Leonidas ;

McGuire, Andrew T. ;

Larochelle, Catherine ;

Uchil, Pradeep ;

Lu, Maolin ;

Mothes, Walther ;

De Serres, Gaston ;

Moreira, Sandrine ;

Roger, Michel ;

Richard, Jonathan ;

Martel-Laferriere, Valerie ;

Duerr, Ralf ;

Tremblay, Cecile ;

Kaufmann, Daniel E. ;

Finzi, Andres .

CELL HOST & MICROBE, 2021, 29 (07) :1137-+

[36] SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice [J].

Tian, Jing-Hui ;

Patel, Nita ;

Haupt, Robert ;

Zhou, Haixia ;

Weston, Stuart ;

Hammond, Holly ;

Logue, James ;

Portnoff, Alyse D. ;

Norton, James ;

Guebre-Xabier, Mimi ;

Zhou, Bin ;

Jacobson, Kelsey ;

Maciejewski, Sonia ;

Khatoon, Rafia ;

Wisniewska, Malgorzata ;

Moffitt, Will ;

Kluepfel-Stahl, Stefanie ;

Ekechukwu, Betty ;

Papin, James ;

Boddapati, Sarathi ;

Wong, C. Jason ;

Piedra, Pedro A. ;

Frieman, Matthew B. ;

Massare, Michael J. ;

Fries, Louis ;

Bengtsson, Karin Lovgren ;

Stertman, Linda ;

Ellingsworth, Larry ;

Glenn, Gregory ;

Smith, Gale .

NATURE COMMUNICATIONS, 2021, 12 (01)

[37] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials [J].

Voysey, Merryn ;

Clemens, Sue Ann Costa ;

Madhi, Shabir A. ;

Weckx, Lily Y. ;

Folegatti, Pedro M. ;

Aley, Parvinder K. ;

Angus, Brian ;

Baillie, Vicky L. ;

Barnabas, Shaun L. ;

Bhorat, Qasim E. ;

Bibi, Sagida ;

Briner, Carmen ;

Cicconi, Paola ;

Clutterbuck, Elizabeth A. ;

Collins, Andrea M. ;

Cutland, Clare L. ;

Darton, Thomas C. ;

Dheda, Keertan ;

Dold, Christina ;

Duncan, Christopher J. A. ;

Emary, Katherine R. W. ;

Ewer, Katie J. ;

Flaxman, Amy ;

Fairlie, Lee ;

Faust, Saul N. ;

Feng, Shuo ;

Ferreira, Daniela M. ;

Finn, Adam ;

Galiza, Eva ;

Goodman, Anna L. ;

Green, Catherine M. ;

Green, Christopher A. ;

Greenland, Melanie ;

Hill, Catherine ;

Hill, Helen C. ;

Hirsch, Ian ;

Izu, Alane ;

Jenkin, Daniel ;

Joe, Carina C. D. ;

Kerridge, Simon ;

Koen, Anthonet ;

Kwatra, Gaurav ;

Lazarus, Rajeka ;

Libri, Vincenzo ;

Lillie, Patrick J. ;

Marchevsky, Natalie G. ;

Marshall, Richard P. ;

Mendes, Ana V. A. ;

Milan, Eveline P. ;

Minassian, Angela M. .

LANCET, 2021, 397 (10277) :881-891

[38] Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment [J].

Wouters, Olivier J. ;

Shadlen, Kenneth C. ;

Salcher-Konrad, Maximilian ;

Pollard, Andrew J. ;

Larson, Heidi J. ;

Teerawattananon, Yot ;

Jit, Mark .

LANCET, 2021, 397 (10278) :1023-1034

[39] Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial [J].

Wu, Zhiwei ;

Hu, Yaling ;

Xu, Miao ;

Chen, Zhen ;

Yang, Wanqi ;

Jiang, Zhiwei ;

Li, Minjie ;

Jin, Hui ;

Cui, Guoliang ;

Chen, Panpan ;

Wang, Lei ;

Zhao, Guoqing ;

Ding, Yuzhu ;

Zhao, Yuliang ;

Yin, Weidong .

LANCET INFECTIOUS DISEASES, 2021, 21 (06) :803-812

[40] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial [J].

Xia, Shengli ;

Zhang, Yuntao ;

Wang, Yanxia ;

Wang, Hui ;

Yang, Yunkai ;

Gao, George Fu ;

Tan, Wenjie ;

Wu, Guizhen ;

Xu, Miao ;

Lou, Zhiyong ;

Huang, Weijin ;

Xu, Wenbo ;

Huang, Baoying ;

Wang, Huijuan ;

Wang, Wei ;

Zhang, Wei ;

Li, Na ;

Xie, Zhiqiang ;

Ding, Ling ;

You, Wangyang ;

Zhao, Yuxiu ;

Yang, Xuqin ;

Liu, Yang ;

Wang, Qian ;

Huang, Lili ;

Yang, Yongli ;

Xu, Guangxue ;

Luo, Bojian ;

Wang, Wenling ;

Liu, Peipei ;

Guo, Wanshen ;

Yang, Xiaoming .

LANCET INFECTIOUS DISEASES, 2021, 21 (01) :39-51

← 1 2 3 4 5 →